Autoimmune Hemolytic Anemia Clinical Trial
— TFH and AIHAOfficial title:
Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
NCT number | NCT02828670 |
Other study ID # | AUDIA APJ 2014 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 7, 2016 |
Est. completion date | June 2023 |
T follicular helper (TFH) cells represent a T cell subset dedicated to the activation of B cells. They have been involved in the pathogenesis of autoimmune diseases in humans such as lupus and Sjögren disease. We recently showed that TFH are implicated in the activation of autoreactive B lymphocytes during ITP. Autoimmune hemolytic anemia (AIHA) is an autoimmune disease due to antibodies targeting red blood cells. To date, the role of TFH in the pathogenesis of AIHA is not known. We hypothesize that AIHA is associated with an increase in the number and/or function of TFH, that could participate in the activation of autoreactive B lymphocytes.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 2023 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with a diagnosis of warm AIHA defined by - Hemoglobin <11 g/dl - Low haptoglobin level - Positive direct antiglobulin test (IgG or IgG + complement) - Reticulocyte count >120 G/L - Patients - naive to treatment for hemolytic anemia or a in relapse - Older than 18 years - Able to understand written and spoken French - Persons who have provided written consent Control population - Patients who have given consent - Patients over 18 years - Patients with cold agglutinin disease (progressive AIHA and different treatments of warm autoantibody AIHA) can be included as a sub-group of controls - Patients with non-auto-immune hemolytic anemia (constitutional of enzymatic origin, membrane-related,…) can be included as a sub-group of controls Exclusion Criteria: - Patients without national health insurance - Pregnancy or breast-feeding women - Adults under guardianship - Patients with cancer or malignant hemopathy - Patients with an on-going infection - Patients treated with corticoids or immunosuppressants |
Country | Name | City | State |
---|---|---|---|
France | CHU Dijon Bourgogne | Dijon |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Dijon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the proportion of circulating T follicular helper lymphocytes (TFH) in patients with Autoimmune Hemolytic Anemia (AIHA) and in control subjects. | baseline | ||
Primary | the proportion of circulating TFH in patients with Autoimmune Hemolytic Anemia (AIHA), at diagnosis and after 3 months of treatment with steroids | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05057481 -
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
|
Phase 3 | |
Recruiting |
NCT05937828 -
OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
|
||
Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
Completed |
NCT03269292 -
Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
|
||
Recruiting |
NCT05694312 -
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
|
Phase 2 | |
Completed |
NCT03538041 -
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
|
Phase 2 | |
Recruiting |
NCT03918265 -
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
|
Phase 4 | |
Completed |
NCT02389231 -
Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03576742 -
Severe Immune Cytopenia Registry Www.Sic-reg.Org
|
||
Active, not recruiting |
NCT04657094 -
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT02877706 -
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
|
||
Recruiting |
NCT05931718 -
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
|
||
Completed |
NCT02158195 -
Immunopathology of Autoimmune Hemolytic Anemia
|
||
Completed |
NCT00001630 -
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Phase 1 | |
Withdrawn |
NCT04039477 -
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
|
Phase 2 | |
Recruiting |
NCT04024202 -
Data Registry of Auto Immune Hemolytic Anemia
|
||
Not yet recruiting |
NCT05711264 -
Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
|
||
Completed |
NCT02689986 -
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
|
Phase 2 | |
Recruiting |
NCT06212154 -
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
|
Phase 1 | |
Completed |
NCT04057703 -
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
|